Ignyta, Inc.

We are a precision oncology company pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Our goal with this Rx/Dx approach is to discover, develop and commercialize new drugs that target activated cancer genes and pathways for the customized treatment of cancer. We aim to achieve this goal by pairing each of our product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients who are most likely to benefit from the precisely targeted drugs we develop.

Ignyta’s vision is to become the world’s leading precision medicine company, with an integrated approach to "Rx/Dx" in oncology.


Rx/Dx: Targeted therapeutics paired with
companion diagnostics. Learn more...


Core Values: The foundation
of everything we do. Learn more...


See all news